168 related articles for article (PubMed ID: 36018415)
1. MAP kinase and mammalian target of rapamycin are main pathways of gallbladder carcinogenesis: results from bioinformatic analysis of next generation sequencing data from a hospital-based cohort (NCT05404347).
Rajput M; Chigurupati S; Purwar R; Shukla M; Pandey M
Mol Biol Rep; 2022 Nov; 49(11):10153-10163. PubMed ID: 36018415
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
3. Identification of invasion-metastasis associated MiRNAs in gallbladder cancer by bioinformatics and experimental validation.
Cao J; Shao H; Hu J; Jin R; Feng A; Zhang B; Li S; Chen T; Jeungpanich S; Topatana W; Tian Y; Lu Z; Cai X; Chen M
J Transl Med; 2022 Apr; 20(1):188. PubMed ID: 35484565
[TBL] [Abstract][Full Text] [Related]
4. Unravelling of the comparative Transcriptomic Profile of Gallbladder Cancer using mRNA sequencing.
Dixit R; Pandey M; Rajput M; Shukla VK
Mol Biol Rep; 2022 Jul; 49(7):6395-6403. PubMed ID: 35469389
[TBL] [Abstract][Full Text] [Related]
5. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
6. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.
Mohri D; Ijichi H; Miyabayashi K; Takahashi R; Kudo Y; Sasaki T; Asaoka Y; Tanaka Y; Ikenoue T; Tateishi K; Tada M; Isayama H; Koike K
J Gastroenterol; 2016 Jul; 51(7):711-21. PubMed ID: 26614007
[TBL] [Abstract][Full Text] [Related]
7. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.
Frenel JS; Carreira S; Goodall J; Roda D; Perez-Lopez R; Tunariu N; Riisnaes R; Miranda S; Figueiredo I; Nava-Rodrigues D; Smith A; Leux C; Garcia-Murillas I; Ferraldeschi R; Lorente D; Mateo J; Ong M; Yap TA; Banerji U; Gasi Tandefelt D; Turner N; Attard G; de Bono JS
Clin Cancer Res; 2015 Oct; 21(20):4586-96. PubMed ID: 26085511
[TBL] [Abstract][Full Text] [Related]
8. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract][Full Text] [Related]
9. Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells.
Chen K; Zhu P; Chen W; Luo K; Shi XJ; Zhai W
Aging (Albany NY); 2021 Sep; 13(18):22502-22515. PubMed ID: 34580235
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
11. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.
Schwaederle M; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cell Cycle; 2015; 14(14):2355-61. PubMed ID: 26030731
[TBL] [Abstract][Full Text] [Related]
12. Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway.
Jahn SW; Kashofer K; Thüringer A; Abete L; Winter E; Eidenhammer S; Viertler C; Tavassoli F; Moinfar F
Am J Pathol; 2016 Jan; 186(1):15-23. PubMed ID: 26718977
[TBL] [Abstract][Full Text] [Related]
13. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
15. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways.
Campbell M; Allen WE; Sawyer C; Vanhaesebroeck B; Trimble ER
Circ Res; 2004 Aug; 95(4):380-8. PubMed ID: 15242975
[TBL] [Abstract][Full Text] [Related]
16. Stepwise correlation of TP53 mutations from pancreaticobiliary maljunction to gallbladder carcinoma: a retrospective study.
Kawakami S; Takano S; Fukasawa M; Shindo H; Takahashi E; Fukasawa Y; Hayakawa H; Kuratomi N; Kadokura M; Hosomura N; Amemiya H; Kawaida H; Kono H; Maekawa S; Ichikawa D; Enomoto N
BMC Cancer; 2021 Nov; 21(1):1245. PubMed ID: 34798839
[TBL] [Abstract][Full Text] [Related]
17. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
18. STYK1 promotes cancer cell proliferation and malignant transformation by activating PI3K-AKT pathway in gallbladder carcinoma.
Hu YP; Wu ZB; Jiang L; Jin YP; Li HF; Zhang YJ; Ma Q; Ye YY; Wang Z; Liu YC; Chen HZ; Liu YB
Int J Biochem Cell Biol; 2018 Apr; 97():16-27. PubMed ID: 29413947
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
20. A Novel
De Paolis E; Urbani A; Salvatore L; Foca L; Tortora G; Minucci A; Concolino P
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
